Day: April 11, 2022

TORONTO, April 11, 2022 (GLOBE NEWSWIRE) — VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) is pleased to announce a multi-year regional licensing agreement of subsidiary Transforming Systems (“TS”) SHREWD suite of solutions with NHS England and NHS Improvement Midlands (“NHSEI” or the “Customer”). This transaction marks a new customer sale for the Company, with TS having engaged with NHSEI since July 2021. The Customer, NHSEI, provides care for a population of 10.5 million people, across a very diverse and large region, including areas like Birmingham which is the UK’s second largest city, and Lincolnshire, which is the second largest English county in the country. The work of NHSEI involves supporting the 11 Integrated Care Systems (“ICSs”) and Sustainability and Transformation Plans (“STPs”), 42 trusts and 39 Clinical...

NEW YORK and BOSTON, April 11, 2022 (GLOBE NEWSWIRE) — Worlds Inc. (OTCQB: WDDD), a pioneer that developed the first 3D metaverses and technologies crucial to interactive online multi-player gaming technologies, today announces a partnership with CrossTower Inc., one of the world’s top rated cryptocurrency exchanges. Worlds will utilize CrossTower’s global non-fungible token (NFT) marketplace and services to sell NFTs of digital art, avatars, and other artifacts related to the first online interactive virtual worlds (now known as metaverses) created for some of the most famous music and entertainment artists and brands, such as Aerosmith, David Bowie, New York Yankees, DMC, WWE, and Coca-Cola. NFTs represent ownership of digital assets, including digital art, music, and gaming collectibles through blockchain technology. Consumers...

SANTA CLARA, Calif., April 11, 2022 (GLOBE NEWSWIRE) — Applied Materials, Inc. today announced the recipients of its 2022 Supplier Excellence Awards for contributions made to Applied’s business over the past year. The awards reflect outstanding technical and operational performance in several areas including quality, service, lead time, delivery, cost and responsiveness. “Having deep engagements throughout the supply chain is more critical than ever as we work together in new ways to address the current and future needs of the semiconductor industry,” said Dr. Gino Addiego, Senior Vice President of Semiconductor Global Operations and Corporate Quality at Applied Materials. “Applied thanks all its suppliers, particularly those receiving 2022 Supplier Excellence Awards, for their tremendous support and collaboration.” The following...

KNOXVILLE, TN, April 11, 2022 (GLOBE NEWSWIRE) — Provectus (OTCQB: PVCT) today announced that preclinical research on systemic administration of investigational cancer immunotherapy PV-10 (rose bengal sodium) for the treatment of high-risk and refractory adult solid tumor cancers is being presented at the annual meeting of the American Association for Cancer Research (AACR), being held April 8-13, 2022 in New Orleans, Louisiana. This PV-10 research has been led by Aru Narendran, MD, PhD and his team from the Cumming School of Medicine at the University of Calgary in Calgary, Alberta, Canada. Dr. Narendran and his colleagues previously showed that PV-10 induced cell death at pharmacologically-relevant concentrations in a panel of phenotypically-diverse adult solid tumor cell lines comprising breast, colorectal, head and neck, and...

– Ongoing experiments will evaluate the functionality and efficacy of the B7H3 TriKE in vivo– Future studies will also involve assessments of the B7H3 TriKE efficacy in the HNSCC tumor microenvironment BRISBANE, Calif., April 11, 2022 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (“the Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary tri-specific natural killer (NK) cell engager, TriKE® protein biologic technology platform, announced today that it is presenting pre-clinical data at the American Association For Cancer Research Annual Meeting 2022. The poster presentation titled, “#3435: GTB-5550 (cam16-IL15-camB7H3) Tri-specific Killer Engager (TriKE®) Drives NK Cell Activation and ADCC against Head and Neck Squamous Cell...

Lead clinical-stage oral progesterone receptor (PR) antagonist ONA-XR demonstrates strong efficacy across multiple PR+ solid tumor models First presentation of preclinical CLDN6xCD3 bispecific antibody optimization, binding properties, and T-cell dependent cytotoxicity Context to host webinar with AACR presenters on Wednesday, April 13, 2022, at 11 a.m. ET PHILADELPHIA, April 11, 2022 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced encouraging preclinical data from two pipeline programs, including in vivo combination and immunomodulation data evaluating onapristone extended release (ONA-XR), the company’s lead clinical program. The data are being presented...

CALGARY, Alberta, April 11, 2022 (GLOBE NEWSWIRE) — Canacol Energy Ltd. (“Canacol” or the “Corporation”) (TSX: CNE; OTCQX: CNNEF; BVC: ‎CNEC) is pleased to report on the conventional natural gas prospective resources (resources other than reserves) ‎for its Pola-1 prospect on the VMM-45 exploration block located in the Middle Magdalena Valley (“MMV”) basin of Colombia (the “Audited Area”). Boury Global Energy Consultants Ltd. (“BGEC”), Canacol’s independent qualified resources auditor, ‎was ‎commissioned ‎to conduct an independent prospective resources audit of Canacol’s internal ‎estimates of prospective ‎resources for ‎the Audited Area effective December 31, 2021‎ (the “BGEC ‎Report”). ‎ Canacol is a natural gas focused exploration and production ‎company, and the largest independent gas producer in Colombia.‎ VMM-45 is one of...

WINTER PARK, Fla., April 11, 2022 (GLOBE NEWSWIRE) — CTO Realty Growth, Inc. (NYSE: CTO) (the “Company” or “CTO”) today announced it has entered into a preferred equity agreement to provide $30.0 million of funding towards the acquisition of the Watters Creek at Montgomery Farm grocery-anchored, mixed-use property in Allen, Texas (the “Preferred Investment”). Watters Creek at Montgomery Farm is approximately 458,000 square feet of grocery-anchored retail and office, anchored by Market Street, Anthropologie, Mi Cocina, DSW, The Cheesecake Factory, Brio Italian Grille, and Michaels, and includes a variety of national and local retailers and restaurants (the “Watters Creek Property” or “Property”). “As we’ve seen cap rates for well-located retail and mixed-use assets compress over the past twelve months, we’re selectively making structured...

VANCOUVER, British Columbia, April 11, 2022 (GLOBE NEWSWIRE) — Solaris Resources Inc. (TSX: SLS; OTCQB: SLSSF) (“Solaris” or “the Company”) is pleased to report assay results from a series of additional holes from mineral resource growth drilling at its Warintza Project (“Warintza” or “the Project”) in southeastern Ecuador. Highlights are listed below, with detailed results in Tables 1-2. Key Takeaways Since the discovery of Warintza East in mid-2021, approximately 1km east of Warintza Central, limited drilling has been completed on the open area between the two deposits that would fall into the eastern sector of the conceptual pit design for Warintza Central as uncategorized waste – these results now establish continuity of mineralization between the two deposits with Warintza East remaining entirely open and undrilled to the...

DEER PARK, Ill., April 11, 2022 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its cysteine hydrochloride abbreviated new drug application (ANDA), a bioequivalent generic of Exela Pharma Sciences’ Elcys™. Eton was granted 180 days of generic exclusivity as a result of being the first ANDA submitted against the reference product. The 180-day exclusivity period will begin upon Eton’s commercialization of the product. “We are pleased to see another one of our products receive FDA approval. Despite Exela’s attempts to monopolize a decades old treatment with patents that we believe to be frivolous, we are eager...